AMPICILLIN

Posology Usual adult dosage Ear, nose and throat infections: 250mg four times a day.

Bronchitis:

Routine therapy: 250mg four times a day. High-dosage therapy: 1 g four times a day. Pneumonia: 500 mg four times a day. Urinary tract infections: 500 mg three times a day. Gonorrhoea: 2 g orally with 1 g probenecid as a single dose. Repeated doses are recommended for the treatment of females.

Gastro-intestinal infections: 500-750 mg three to four times daily.

Enteric fevers:

Acute 1-2 g four times a day for two weeks Carriers: 1-2 g four times a day for four to twelve weeks Usual dosage for the elderly As for adults: reduced doses may be required in those with impaired renal function. Usual dosage in paediatric population (children under 10 years) Half adult routine dosage.

All recommended dosages are a guide only. In severe infections the above dosages may be increased, or Ampicillin given by injection. Oral doses of ampicillin should be taken half to one hour before meals. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Consult local or national prescribing guidelines for antibiotic use before prescribing. Where possible, use only where antibiotic sensitivity is known or suspected.

Renal Impairment:

In the presence of severe renal impairment (creatinine clearance <10ml/min) a reduction in dose or extension of dose interval should be considered. In cases of dialysis, an additional dose should be administered after the procedure.

Method of administration Route of administration:

Oral

Side effects are mainly of a mild and transitory nature.

Gastro-intestinal reactions:

Effects include diarrhoea, vomiting, and nausea. Pseudomembraneous colitis and haemorrhagic colitis have been reported occasionally.

Hypersensitivity reactions:

If any hypersensitivity reaction occurs, the treatment should be discontinued. Skin rash, pruritis and urticaria have been reported occasionally. The incidence is higher in patients suffering from infectious mononucleosis and acute or chronic leukaemia of lymphoid origin.

Purpura has also been reported. Rarely, skin reactions such as erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. 4) has been reported rarely.

Renal effects:

Interstitial nephritis has been reported.

Hepatic effects:

As with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely. As with most other antibiotics, a moderate and transient increase in transaminases has been reported.

Haematological effects:

As with other beta-lactams, haematological effects including transient leucopenia, transient thrombocytopenia and haemolytic anaemia have been reported rarely. Prolongation of bleeding time and prothrombin have also been reported rarely.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

g. Candida or Pseudomonas. Anaphylactic (anaphylactoid) reactions Before initiating therapy with ampicillin, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics. Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics.

Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity. Use in patients with infections Ampicillin should be avoided if infectious mononucleosis and/or acute and chronic lymphatic leukaemia are suspected as erythematous rashes are more common with these conditions following the administration of ampicillin.

2). Sodium This medicine contains less than 1mmol sodium (23 mg) per capsule, that is to say essentially “sodium free”.

g. 1.